Thromboprophylaxis in total hip-replacement surgery in Europe: Acenocoumarol, fondaparinux, dabigatran and rivaroxban

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 7, Issue 1, 2007, Pages 49-58

  Ivanovic, Natasa ^a,b   Beinema, Maarten ^b,c   Brouwers, Jacobus R B J ^b,d   Naunton, Mark ^b   Postma, Maarten J ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c DEVENTER HOSPITAL   (Netherlands)

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Acenocoumarol; Cost effectiveness; Dabigatran; Direct thrombin inhibitors; Fondaparinux; Rivaroxban; Thromboprophylaxis; Total hip replacement

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; PLACEBO; REVIPARIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTIVE SURGERY; EUROPE; HEALTH CARE COST; HIP OSTEOARTHRITIS; HUMAN; INCIDENCE; LIVER TOXICITY; LUNG EMBOLISM; META ANALYSIS; PHLEBOGRAPHY; POSTTHROMBOSIS SYNDROME; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

EID: 33847055848     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.7.1.49     Document Type: Review

References (35)

1. Brunenberg DE, van Steyn MJ, Sluimer JC, Bekebrede LL, Bulstra SK, Joore MA. Joint recovery program versus usual care: an economic evaluation of a clinical pathway for joint replacement surgery. Med. Care 43, 1018-1026 (2005).
2. Eriksson BI, Dahl OE. Prevention of venous thromboembolism following orthopedic surgery: clinical potential of direct thrombin inhibitors. Drugs 64(6), 577-595 (2004).
3. Ostendorf M, Johnell O, Malchau H, Dhert WJA, Sckrijvers AJP, Verbout AJ. The epidemiology of total hip replacement in The Netherlands and Sweden: present status and future needs. Acta Orthop. Scand. 73(3), 282-286 (2002).
4. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3), 338-400 (2004).
5. Samama CM, Albaladejo P, Benhamou D et al. Venous thromboembolism prevention in surgery and obstetrics: clinical practice guidelines. Eur. J. Anaesthesiol. 23(2), 95-116 (2006).
6. Buller HR, van der Meer J, Oudkerk M. CBO guideline. Deep venous thrombosis and pulmonary embolism; revision of the earlier guidelines. Dutch Organization for Quality Assurance in Hospitals. Ned. Tijdschr. Geneeskd. 144(32), 1531-1537 (2000).
7. Ettema HB, Hoppener MR, Henny CP, Buller HR, Verheyen CCPM. Compliance of Dutch orthopedic departments with national guidelines on thromboprophylaxis. A survey of Dutch orthopedic thromhoprophylaxis. Acta Orthop. 76(1), 99-103 (2005).
8. Schonenberg D, van Meeteren M, Nelissen RGHH, van der Horst-Bruinsma IE, Pöll RG, Nurmohamed MT. Thrombosis prevention in orthopedic surgery: clinical practice in the Netherlands in 2002. Ned. Tijdschr. Geneeskd. 147(38), 1856-1860 (2003).
9. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 359(9319), 1715-1720 (2002).
10. Swierstra BA, Stibbe J, Schouten HJA. Prevention of thrombosis after hip arthroplasty. A prospective study of preoperative oral anticoagulants. Acta Orthop. Scand. 59(2), 139-143 (1988).
11. Samama CM, Vray M, Barre J et al. SACRE Study Investigators. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch. Intern. Med. 162(19), 2191-2196 (2002).
12. Hamulyak K, Lensing AWA, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb. Haemost. 74(6), 1428-1431 (1994).
13. Eriksson BI, Dahl OE, Buller HR et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3(1), 103-111 (2005).
14. Eriksson BI, Borris L, Dahl OE et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement J. Thromb. Haemost. 4(1), 121-128 (2006).
15. Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J. Thromb. Haemost. 2(7), 1058-1070 (2004).
16. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 162(16), 1833-1840 (2002).
17. Di Nisio M, Middeldorp S, Buller HR. Direct thrombin inhibitors. N. Engl. J. Med. 353(10), 1028-1040 (2005).
18. Colwell C, Mouret P. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Semin. Vasc. Med. 5(3), 266-275 (2005).
19. Annemans L, Minjoulat-Rey MC, De Knock M et al. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery in Belgium. Acta Clin. Belg. 59(6), 346-357 (2004).
20. Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am. J. Cardiovasc. Drugs 5(2), 121-130 (2005).
21. Gordois A, Posnett J, Borris L et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J. Thromb. Haemost. 1(10), 2167-2174 (2003).
22. Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden. Eur. J. Health Econ. 4(4), 254-262 (2003).
23. Wade WE, Spruill WJ, Leslie RB. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am. J. Orthop. 32(4), 201-205 (2003).
24. Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molccular-weight heparin in elective hip surgery? Arch. Intern. Med. 162(13), 1451-1456 (2002).
25. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial. Lancet 359(93), 1721-1726 (2002).
26. Agnelli G, Sonaglia F. Prevention of venous thromboembolism in high risk patients. Haematologica 82(4), 496-502 (1997).
27. Dobesh PP. Evidence for extended prophylaxis in the setting of orthopedic surgery. Pharmacotherapy 24(7), 73-81 (2004).
28. Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E. A clinical decision support system for prevention of venous thromboembolism: effict on physician behavior. JAMA 283(21), 2816-2821 (2000).
29. Ellis MH, Elis A. Perioperative venous thromboembolism prophylaxis in Israel: a survey of academic surgical departments. Eur. J. Haematol. 73(2), 104-108 (2004).
30. Verhaeghe R. Extended prophylaxis of venous thromboembolism in major orthopedic surgery. Acta Orthop. Belg. 71(3), 255-259 (2005).
31. Stratton MA, Anderson FA, Bussey HI et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch. Intern. Med. 160(3), 334-340 (2000).
32. Kakkar AK, Davidson BL, Haas SK. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J. Thromb. Haemost. 2(2), 221-227 (2004).
33. Samama MM, Dahl OE, Mismetti P et al. An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica 91(1), 64-70 (2006).
34. van Geest-Daalderop JHH, Sturk A, Levi M, Adriaansen HJ. Extent and quality of anti-coagulation treatment with coumarin derivatives by the Dutch Thrombosis Services. Ned. Tijdschr. Geneeskd. 148(15), 730-735 (2004).
35. Schalekamp, T, van Geest-Daalderop JHH, de Vries-Goldschmeding H, Conemans J, Bernsen MJ, de Boer A. Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clin. Pharmacol. Ther. 75(5), 394-402 (2004).